Session description:
This session will discuss the latest advancements in clinical trials for diabetic kidney disease treatment. While the session will review and analyze the key clinical trials of novel agents used for diabetic nephropathy, there will be a discussion of a personalized approach to managing novel agents.
Learning objectives:
Review and analyze the key clinical trials involving GLP1RA, MRA, and SGLT2i therapies. Identify each therapy's outcomes, patient profiles, and effectiveness based on trial data.Explore the comparative efficacy of solo and combination GLP1RA, MRA, and SGLT2i therapies in treating diabetic kidney disease. Understand the various personalized approaches to the treatment of diabetic kidney diseases.
| Time | Session |
|---|
|
11:30 a.m.
12 p.m.
|
Clinical Trials Overview: Focus on GLP1a, MRA, and SGLT2
Neelkamal Hall 305
|
|
12 p.m.
12:30 p.m.
|
SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
KatherineTuttle
Speaker
University of Washington School of Medicine, Division of NephrologyUnited States
Neelkamal Hall 305
|
|
12:30 p.m.
1 p.m.
|
SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
Neelkamal Hall 305
|
|
1 p.m.
1:30 p.m.
|
Q and A
Neelkamal Hall 305
|